Literature DB >> 25110234

Dichloroacetate prevents but not reverses the formation of neointimal lesions in a rat model of severe pulmonary arterial hypertension.

Bingbing Li1, Jie Yan2, Yan Shen1, Yong Liu3, Zhengliang Ma1.   

Abstract

The formation of neointimal lesions is one of the characteristic pathological alterations of the pulmonary vasculature in response to sustained pulmonary arterial hypertension (PAH). To date, the effect of dichloroacetate (DCA) on these intimal lesions had remained to be investigated. In the present study, the beneficial impact of DCA on the formation of neointimal lesions was examined in rats treated with monocrotaline following pneumonectomy. The rats were subjected to monocrotaline subcutaneous injection seven days following left pneumonectomy and received DCA by gastric gavage (80 mg/kg/day) for 20 days. At the end of the experiments, hemodynamic measurement was performed prior to the excision of the rats' right lungs for further morphometric and immunoblot analysis. Furthermore, the activity of reactive oxygen species (ROS), superoxide dismutase (SOD) in the lungs was examined by a colorimetric assay. The results revealed that DCA treatment from day 8-28 following pneumonectomy caused a marked reduction in pulmonary arterial pressure and amelioration in right ventricle hypertrophy (mean pulmonary arterial pressure, 24±2.8 vs. 33±5.5 mmHg; right ventricle-to-left ventricle + intra-ventricle septum ratio, 29±2.8 vs. 43±3.3%; P<0.05) and pulmonary arterioles intimal proliferation (grade 1 and 2 occlusion, 24 and 20% vs. 44 and 40%; P<0.05) in pulmonary hypertensive rats. By contrast, DCA treatment initiated 29 days following pneumonectomy did not result in any improvement in pulmonary circulatory parameters or regression of occlusive neointimal lesions. Immunohistochemical and immunoblot assays demonstrated markedly reduced hypoxia inducible factor (HIF-1α) levels, and increased voltage-dependent potassium channel subtype 1.5 (Kv1.5) expression levels were observed in those neointimal regions in rats receiving DCA preventive therapy. Furthermore, preventive treatment with DCA significantly increased the activity of copper/zinc superoxide dismutase (Cu/Zn SOD activity, 88±4.2 vs. 53±2.7 U/mgprot; P<0.05) and promoted the degradation of ROS (106±4.7 vs. 79±13.3 U/mgprot; P<0.05), which was compromised in the delayed intervention group. Therefore, DCA is effective to prevent the formation of intimal lesions, which may be attributed to the induction of the upregulation of Cu/Zn SOD activity and the suppression of HIF-1α activation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25110234     DOI: 10.3892/mmr.2014.2432

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

1.  Rats with a Human Mutation of NFU1 Develop Pulmonary Hypertension.

Authors:  Maki Niihori; Cody A Eccles; Sergey Kurdyukov; Marina Zemskova; Mathews Valuparampil Varghese; Anna A Stepanova; Alexander Galkin; Ruslan Rafikov; Olga Rafikova
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

Review 2.  Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Authors:  Jessica B Badlam; Todd M Bull
Journal:  Ther Adv Chronic Dis       Date:  2017-03-01       Impact factor: 5.091

Review 3.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

Review 4.  Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.

Authors:  Keshava Rajagopal; Andrew J Bryant; Sandeep Sahay; Nancy Wareing; Yang Zhou; Lavannya M Pandit; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

Review 5.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

6.  Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension.

Authors:  Ke Yuan; Ning-Yi Shao; Jan K Hennigs; Marielle Discipulo; Mark E Orcholski; Elya Shamskhou; Alice Richter; Xinqian Hu; Joseph C Wu; Vinicio A de Jesus Perez
Journal:  Am J Pathol       Date:  2016-07-25       Impact factor: 4.307

Review 7.  Emerging therapeutics in pulmonary hypertension.

Authors:  Matthew K Hensley; Andrea Levine; Mark T Gladwin; Yen-Chun Lai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-01       Impact factor: 5.464

8.  BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).

Authors:  Andrea Frump; Allison Prewitt; Mark P de Caestecker
Journal:  Pulm Circ       Date:  2018-03-09       Impact factor: 3.017

9.  Therapeutic effect of dichloroacetate against atherosclerosis via hepatic FGF21 induction mediated by acute AMPK activation.

Authors:  Byong-Keol Min; Chang Joo Oh; Sungmi Park; Ji-Min Lee; Younghoon Go; Bo-Yoon Park; Hyeon-Ji Kang; Dong Wook Kim; Jeong-Eun Kim; Eun Kyung Yoo; Hui Eon Kim; Mi-Jin Kim; Yong Hyun Jeon; Yong-Hoon Kim; Chul-Ho Lee; Jae-Han Jeon; In-Kyu Lee
Journal:  Exp Mol Med       Date:  2019-09-30       Impact factor: 8.718

Review 10.  Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.

Authors:  Stevan P Tofovic; Edwin K Jackson
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.